Pharscin Pharma(SZ:002907) Zheng Quan Zhi Xing·2025-08-21 09:14Core Viewpoint - The document outlines the information disclosure management measures for Chongqing Huasen Pharmaceutical Co., Ltd, aiming to establish a sound information disclosure system, regulate the behavior of information disclosers, and protect investors' rights and interests [1]. Group 1: Information Disclosure Obligations - Information disclosers must fulfill their obligations in a timely manner, ensuring that the information is true, accurate, complete, and easy to understand, without any false records or misleading statements [3][4]. - Information must be disclosed simultaneously to all investors, and no advance disclosure is allowed to any individual or entity [3][4]. - The company and its related parties must ensure that any voluntarily disclosed information is also true, accurate, and complete, adhering to the principle of fairness [3][4]. Group 2: Disclosure Procedures and Responsibilities - The board of directors is responsible for leading and managing the company's information disclosure affairs, with the chairman being the primary responsible person and the board secretary handling the direct responsibilities [6][8]. - The company must disclose significant events that may impact stock trading prices immediately, explaining the cause, current status, and potential effects [15][16]. - The board secretary is tasked with organizing and coordinating information disclosure activities, ensuring compliance with regulations and maintaining confidentiality of insider information [7][8]. Group 3: Reporting Standards and Timelines - The company is required to disclose periodic reports, including annual, semi-annual, and quarterly reports, within specified timeframes after the end of each accounting period [20][21]. - Financial reports in annual disclosures must be audited by a qualified accounting firm, while semi-annual reports may not require an audit unless specific conditions are met [12][21]. - Companies must issue performance forecasts if they anticipate significant changes in earnings, such as a net profit loss or a change of 50% or more compared to the previous year [29][30]. Group 4: Confidentiality and Compliance - The company must maintain confidentiality regarding undisclosed information and ensure that only a limited number of individuals have access to sensitive information [26][27]. - Any violations of disclosure regulations may lead to disciplinary actions and potential legal consequences for responsible individuals [70][71]. - The company must regularly review its information disclosure practices and take corrective actions if any issues are identified [67][71].